BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
| Image |  |
|---|---|
| Description | scientific article published on 10 April 2014 |
| Author/s |
author: Suzanne Kamel-Reid |
| Publication date | April 10, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |